Treatment-induced Damage to the Tumor Microenvironment Promotes Prostate Cancer Therapy Resistance Through WNT16B

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2012 Aug 7

PMID 22863786

Citations 403

Authors

Yu Sun

Judith Campisi

Celestia Higano

Tomasz M Beer

Peggy Porter

Ilsa Coleman

Lawrence True

Peter S Nelson

Affiliations

Soon will be listed here.

Abstract

Acquired resistance to anticancer treatments is a substantial barrier to reducing the morbidity and mortality that is attributable to malignant tumors. Components of tissue microenvironments are recognized to profoundly influence cellular phenotypes, including susceptibilities to toxic insults. Using a genome-wide analysis of transcriptional responses to genotoxic stress induced by cancer therapeutics, we identified a spectrum of secreted proteins derived from the tumor microenvironment that includes the Wnt family member wingless-type MMTV integration site family member 16B (WNT16B). We determined that WNT16B expression is regulated by nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB) after DNA damage and subsequently signals in a paracrine manner to activate the canonical Wnt program in tumor cells. The expression of WNT16B in the prostate tumor microenvironment attenuated the effects of cytotoxic chemotherapy in vivo, promoting tumor cell survival and disease progression. These results delineate a mechanism by which genotoxic therapies given in a cyclical manner can enhance subsequent treatment resistance through cell nonautonomous effects that are contributed by the tumor microenvironment.

Citing Articles

Inflammation in cancer: therapeutic opportunities from new insights.

Xie Y, Liu F, Wu Y, Zhu Y, Jiang Y, Wu Q Mol Cancer. 2025; 24(1):51.

PMID: 39994787 PMC: 11849313. DOI: 10.1186/s12943-025-02243-8.

Desmoplastic reaction in the microenvironment of head and neck and other solid tumors: the therapeutic barrier.

Okuyama K, Tsuchiya M, Debnath K, Islam S, Yanamoto S Ther Adv Med Oncol. 2025; 17:17588359251317144.

PMID: 39926258 PMC: 11806477. DOI: 10.1177/17588359251317144.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

The roles of cancer stem cells and therapeutic implications in melanoma.

Mu X, Zhou Y, Yu Y, Zhang M, Liu J Front Immunol. 2024; 15:1486680.

PMID: 39611156 PMC: 11602477. DOI: 10.3389/fimmu.2024.1486680.

Establishment of a tumor-associated fibroblast associated gene score based on scRNA-seq to predict prognosis in patients with triple-negative breast cancer.

Yu H, Peng Z, Li X, Zhang Y PLoS One. 2024; 19(10):e0311801.

PMID: 39418248 PMC: 11486389. DOI: 10.1371/journal.pone.0311801.

References

Gilbert L, Hemann M . DNA damage-mediated induction of a chemoresistant niche. Cell. 2010; 143(3):355-66. PMC: 2972353. DOI: 10.1016/j.cell.2010.09.043. View

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, van der Horst C . BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436(7051):720-4. DOI: 10.1038/nature03890. View

Huang S, Mishina Y, Liu S, Cheung A, Stegmeier F, Michaud G . Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009; 461(7264):614-20. DOI: 10.1038/nature08356. View

Kuilman T, Peeper D . Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 2009; 9(2):81-94. DOI: 10.1038/nrc2560. View

Redmond K, Wilson T, Johnston P, Longley D . Resistance mechanisms to cancer chemotherapy. Front Biosci. 2008; 13:5138-54. DOI: 10.2741/3070. View

Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden J . Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 2011; 25(20):2125-36. PMC: 3205583. DOI: 10.1101/gad.17276711. View

Acosta J, OLoghlen A, Banito A, Guijarro M, Augert A, Raguz S . Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008; 133(6):1006-18. DOI: 10.1016/j.cell.2008.03.038. View

Fumagalli M, dAdda di Fagagna F . SASPense and DDRama in cancer and ageing. Nat Cell Biol. 2009; 11(8):921-3. DOI: 10.1038/ncb0809-921. View

10.

Wajapeyee N, Serra R, Zhu X, Mahalingam M, Green M . Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008; 132(3):363-74. PMC: 2266096. DOI: 10.1016/j.cell.2007.12.032. View

11.

Coppe J, Kauser K, Campisi J, Beausejour C . Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem. 2006; 281(40):29568-74. DOI: 10.1074/jbc.M603307200. View

12.

Alderton P, Gross J, Green M . Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992; 52(1):194-201. View

13.

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

14.

In Yook J, Li X, Ota I, Hu C, Kim H, Kim N . A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 2006; 8(12):1398-406. DOI: 10.1038/ncb1508. View

15.

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

16.

Beer T, Garzotto M, Lowe B, Ellis W, Montalto M, Lange P . Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2004; 10(4):1306-11. DOI: 10.1158/1078-0432.ccr-1021-03. View

17.

Bavik C, Coleman I, Dean J, Knudsen B, Plymate S, Nelson P . The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006; 66(2):794-802. DOI: 10.1158/0008-5472.CAN-05-1716. View

18.

Binet R, Ythier D, Robles A, Collado M, Larrieu D, Fonti C . WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res. 2009; 69(24):9183-91. PMC: 7439003. DOI: 10.1158/0008-5472.CAN-09-1016. View

19.

Kobayashi H, Man S, Graham C, Kapitain S, Teicher B, Kerbel R . Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A. 1993; 90(8):3294-8. PMC: 46286. DOI: 10.1073/pnas.90.8.3294. View

20.

Vincan E, Barker N . The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis. 2008; 25(6):657-63. DOI: 10.1007/s10585-008-9156-4. View